1. Cohen KA, Hopkins J, Ingraham RH, et al. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem. 1991;266:14670–14674. [PubMed] 2. Harris M, Montaner JS. Clinical uses of non-nucleoside reverse transcriptase inhibitors. Rev Med Virol. 2000;10:217–229. [PubMed] 3. Easterbrook PJ, Newson R, Ives N, et al. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J Acquir Immune Defic Syndr. 2001;27(4):350–364. [PubMed]
4. Montaner JS, Hall D, Carlier H, et al. Analyses of four key clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4 levels, hepatitis B and C seropositivity, and baseline liver functions tests [abstract]. 10th Annual Canadian Conference on HIV/AIDS Research; May 31–Jun 3; Toronto (ON). 2001.
5. Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34 Suppl. 1:S21–S33. [PubMed]
6. Viramune® (nevirapine) tablets and oral suspension [product information] Ingelheim: Boehringer Ingelheim; 2007. Aug,
7. Marazzi MC, Germano P, Liotta G, et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med. 2006 Jul;7(5):338–344. [PubMed]
8. WHO. Geneva: WHO Press; 2006. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access.
9. Scheetz MH, McKoy JM, Parada JP, et al. Systematic review of piperacillin-induced neutropenia. Drug Saf. 2007;30(4):295–306. [PubMed] 10. Bennett CL, Nebeker JR, Yarnold PR, et al. Evaluation of serious adverse drug reactions: a proactive pharmaco-vigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med. 2007 May 28;167(10):1041–1049. [PubMed] 11. Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA. 2005;293(17):2131–2140. [PubMed] 12. Muro E, Droste JA, Hofstede HT, et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr. 2005;39(4):419–421. [PubMed] 13. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006) AIDS. 1999;13(4):479–486. [PubMed]
14. Lyons F, Hopkins S, McGeary A, et al. Nevirapine tolerability in HIV infected women in pregnancy: a word of caution [abstract no. LB27]. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; Jul 13–16; Paris. 2003.
15. AIDS Clinical Trial Group. Table of grading severity of adult adverse experiences. Rockville (MD): Division of AIDS, National Institute of Allergy and Infectious Diseases; 1992.
16. Johnson S, Chan J, Bennett CL. Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen. Ann Intern Med. 2002 Jul 16;137(2):146–147. [PubMed]
17. Yarnold PR, Soltysik RC. Optimal data analysis: a guidebook with software for Windows. Washington, DC: APA Books; 2004.
18. Mirochnick M, Fenton T, Gagnier P, et al. Pediatric AIDS Clinical Trials Group Protocol 250 Team. Pharmaco-kinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis. 1998 Aug;178(2):368–374. [PubMed] 19. Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795–802. [PubMed] 20. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362(9387):859–868. [PubMed] 21. Moodley D, Moodley J, Coovadia H, et al. South African Intrapartum Nevirapine Trial (SAINT) Investigators. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003 Mar 1;187(5):725–735. [PubMed] 22. Lallemant M, Jourdain G, Le Coeur S, et al. Perinatal HIV Prevention Trial (Thailand) Investigators. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004 Jul 15;351(3):217–228. [PubMed] 23. Dorenbaum A, Cunningham CK, Gelber RD, et al. International PACTG 316 Team. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002 Jul 10;288(2):189–198. [PubMed] 24. Hitti J, Frenkel L, Stek A, et al. PACTG 1022 Study Team. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immn Defic Syndr. 2004;36(3):772–776. [PubMed]
25. Kramer F, Stek A, Du WB, et al. Nevirapine tolerability in HIV-infected women in pregnancy [abstract no. 923]. 11th Conference on Retroviruses and Opportunistic Infections; Feb 8–11; San Francisco (CA). 2004.
26. Joao EC, Calvet GA, Menezes JA, et al. Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Am J Obstet Gynecol. 2006;194:199–202. [PubMed]
27. Fregonese F, Maleesatharn A, Ratanakosol J, et al. Six months follow up of highly active antiretroviral therapy (HAART) initiated during pregnancy in Thailand [abstract no. ThPeB7088]. XV International AIDS Conference; Jul 11–16; Bangkok. 2004.
28. Thomas T, Harris J, Greene S, et al. Influence of a safe water system intervention on diarrhea rates among exclusively breastfed infants who were weaned rapidly at 6 months in the Kisumu Breastfeeding Study, Kisumu, Kenya [abstract no. 646]. 15th Conference on Retroviruses and Opportunistic Infections (CROI); Feb 3–6; Boston (MA). 2008.
29. Phanuphak N, Apornpong T, Teeratakulpisarn S, et al. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med. 2007;8(6):357–366. [PubMed]
30. Palombi L, Germano P, Liotta G, et al. HAART in pregnancy: safety, effectiveness and protection from viral resistance: results from the DREAM cohort [abstract no. 67]. 12th Conference on Retroviruses and Opportunistic Infections (CROI); Feb 22–25; Boston (MA). 2005.
31. Money D, Khoo D, MacDonald G, et al. A comparison of toxicity in nevirapine vs protease inhibitor-containing HAART regimens in pregnant women [abstract no. 784]. 12th Conference on Retroviruses and Opportunistic Infections (CROI); Feb 22–25; Boston (MA). 2005.
32. Tonwe-Gold B, Ekouevi D, Rouet F, et al. Highly active antiretroviral therapy for the prevention of perinatal HIV transmission in Africa: mother-to-child HIV transmission plus, Abidjan, Côte d’Ivoire, 2003–2004 [abstract no. 785]. 12th Conference on Retroviruses and Opportunistic Infections (CROI); Feb 22–25; Boston (MA). 2005.
33. Dorenbum-Kracer A, Sullivan J, Gelber R, et al. Antiretroviral use in pregnancy in PACTG 316: a phase III randomized, blinded study of single-dose intrapartum/neonatal nevirapine to reduce mother to infant HIV transmission [abstract no. 23281] Int Conf AIDS. 1998;12:397.
34. Lallemant MG, Thaineua V, Jourdain G, et al. PHPT-2: nevirapine plus zidovudine for the prevention of perinatal HIV [abstract no. C10914]. 14th International Conference on AIDS; Jul 7–12; Barcelona. 2002.
35. Taha TE, Kumwenda N, Gibbons A, et al. Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. AIDS. 2002 Apr 12;16(6):851–858. [PubMed] 36. Shetty AK, Coovadia HM, Mirochnick MM, et al. HIVNET 023 Study Team. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):482–490. [PubMed]
37. Pakker N, Vyankandondera J, Luchters S, et al. Efficacy of postnatal prophylaxis of 3TC or NVP in breastfed children to prevent MTCT through breastfeeding, the SIMBA study. 13th International Conference on STD & AIDS in Africa (ICASA); Sep 21–26; Nairobi. 2003.
38. Rey D, Partisani M, Hess-Kempf G, et al. Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIV. J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1454–1456. [PubMed]
39. Livrozet J, Berra N, Tourain JL, et al. The bill trial: a pilot study assessing the safety of a short-course nevirapine (NVP)-containing regimen as a post exposure prophylaxis (PEP) [abstract no. p58]. 6th International Congress of Drug Therapy in HIV Infection; Nov 17–21; Glasgow. 2002.
40. Puro V, Soldani F, De Carli G, et al. Drug-induced amino-transferase alterations during antiretroviral HIV post-exposure prophylaxis. AIDS. 2003 Sep 5;17(13):1988–1990. [PubMed]
41. Bernasconi E, Ruef C, Jost J, et al. National registry for non-occupational post HIV exposure prophylaxis in Switzerland: two-years results [abstract no. WePeC4312]. The XIII International Conference on AIDS; Jul 9–14; Durban. 2000.
42. Benn PD, Mercey DE, Brink N, et al. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet. 2001 Mar 3;357(9257):687–688. [PubMed] 43. Jackson JB, Barnett S, Piwowar-Manning E, et al. A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. AIDS. 2003 Mar 7;17(4):547–553. [PubMed] 44. Johnson S, Baraboutis JG. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA. 2000;284(21):2722. [PubMed] 45. Sha BE, Proia LA, Kessler HA. Adverse effects associated with use of nevirapine inHIV postexposure prophylaxis for 2 health care workers. JAMA. 2000;284(21):2723. [PubMed]
46. Baylor M, Truffa M, Gibbs N. Hepatic toxicity of anti-retrovirals in HIV-infected pregnant women: a review of FDAs Adverse Event Reporting System [abstract no. 944]. Conference on Retroviruses and Opportunistic Infections (CROI); Feb 8–11; San Francisco (CA). 2004.
47. Timmermans S, Tempelmen C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005;19(8):795–799. [PubMed] 48. Torti C, Costarelli S, De Silvestri A, et al. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. Drug Saf. 2007;30(12):1161–1169. [PubMed] 49. Sissoko D, Ajana F, de la Tribonnière X, et al. Cutaneous, hepatic, and hematologic manifestations due to nevirapine: DRESS syndrome? Presse Med. 2000;29(19):1041–1042. [PubMed] 50. Pilero PJ, Purdy B. Nevirapine-induced hepatitis: a case series and review of the literature. AIDS Read. 2001;11(7):379–382. [PubMed] 51. Bundrow D, Rosoff L, Abaloufia DM. Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain. AIDS Read. 2001;11(11):577–580. [PubMed] 52. Bourezane Y, Salard D, Hoen B, et al. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis. 1998;27(5):1321–1322. [PubMed]
53. Harris M, Montaner JSG. Nevirapine hepatotoxicity: an important clinical issue [editorial comment] AIDS Read. 2001;11:580.
54. Nassif A, Bensussan A, Dorothée G, et al. Drug specific cytotoxicity T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol. 2002;118(4):728–733. [PubMed] 55. Lee BL, Delahunty T, Safrin S. The hydroxylamine of sulfamethoxazole and adverse drug reactions in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther. 1994;56(2):184–189. [PubMed] 56. Dieterich DT, Robinson PA, Love J, et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38 Suppl. 2:S80–S89. [PubMed] 57. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191(6):825–829. [PubMed]
58. Martin A, Cameron P, Nolan D, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*01 and higher CD4+ T cell counts [abstract no. WePeB5866]. 15th International AIDS Conference; Jul 11–16; Bangkok. 2004.
60. Perinatal Prevention Study. Washington, DC: National Academies Press; 2005. Committee on Reviewing the HIVNET 012 Perinatal HIV Prevention Study, Board on Population Health and Public Health Practice. Overview of HIVNET 012.
61. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet. 2007 Nov 17;370(9600):1698–1705. [PubMed]